YOKNEAM, Israel, July 27, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for surgical, ophthalmology and aesthetic applications, announced today its support for the second World Head and Neck Cancer Day, recognized annually on July 27.
IFHNOS World Head & Neck Cancer Day Video https://vimeo.com/user34056276/review/126595650/245eb7762f
Head Neck Squamous Cell Carcinoma (HNSCC) is one of the leading causes of death and disability in many parts of the world: approximately 350,000 people die of the condition each year. While the vast majority of HNSCC can be prevented or cured if detected early, millions of people suffer from delayed diagnosis, inadequate treatment and inappropriate rehabilitation and palliation.
Lumenis, with its advanced AcuPulse™ DUO CO2 laser platform, offers a solution that can remove cancer with fewer disturbances to structures, nerves, and tissue. Unlike open surgery, CO2 lasers are increasingly becoming a first line treatment of early stage airway cancers.1 The CO2 laser solutions offered by Lumenis for Transoral Laser Microsurgery (TLM) technique, propose low morbidity and excellent cure rates compared to chemoradiation.2 Immediate treatment post-surgical biopsy eliminates return visits to the Operating Room and may serve as salvage therapy for select patients with previously treated laryngeal or pharyngeal squamous cell cancer or other pathologies.
"As part of our ongoing commitment to advancing our treatment solutions for better clinical care, we are proud to recognize and support World Head and Neck Cancer Day." Said Tzipi Ozer-Armon, Chief Executive Officer of Lumenis. "Lumenis recognizes the patient's right for easy access to information about their condition and treatment options. We aim to drive patient education and awareness by reaching out to many patients afflicted by this disease and their families."
To access disease information, an overview of available treatments for throat cancer, physician insights and patient stories, please visit www.throat-cancer.com.
Founded by the International Federation of Head and Neck Oncologic Societies (IFHNOS) in 2014, World Head and Neck Cancer Day was established to address the global challenge of HNSCC and to improve public education about prevention, early detection and disease management.
To learn more or find out how you can participate in World Head and Neck Cancer Day, please visit www.ifhnos.org/world-cancer-day.
About the International Federation of Head and Neck Oncology Societies
International Federation of Head and Neck Oncology Societies (IFHNOS) is a global organization established through cooperation of national and regional Societies and Organizations in the specialty of Head and Neck Surgery and Oncology with membership from national and regional multidisciplinary organizations, representing 50 countries. The purpose of this organization is to provide a common platform for specialists in the field of Head and Neck Cancer to interact in professional matters of mutual interest. To know more about IFHNOS visit http://www.ifhnos.org/home
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
1. Schrijvers ML, van Riel EL, Langendijk JA, Dikkers FG, Schuuring E, van der Wal JE, van der Laan BF. Higher laryngeal preservation rate after CO2 laser surgery compared with radiotherapy in T1A glottis laryngeal carcinoma, Head Neck, 2009 Jun; 31(6):759–64.
2. Hinni ML, Salassa JR, Grant DG, Pearson BW, Hayden RE, Martin A, Christiansen H, Haughey BH, Nussenbaum B, Steiner W, Transoral Laser Microsurgery for Advanced Laryngeal Cancer, Arch Otolaryngol Head Neck Surg, 2007 Dec; 133(12):1198-204.
CONTACT: Glenn Silver Lazar Partners Ltd. (646) 871-8495